| SARS-CoV-2 variants B. 1.351 and P. 1 escape from neutralizing antibodies M Hoffmann, P Arora, R Groß, A Seidel, BF Hörnich, AS Hahn, N Krüger, ... Cell 184 (9), 2384-2393. e12, 2021 | 1008 | 2021 |
| Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity M Hoffmann, H Hofmann-Winkler, JC Smith, N Krüger, P Arora, ... EBioMedicine 65, 2021 | 352 | 2021 |
| SARS-CoV-2 variant B. 1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination M Hoffmann, H Hofmann-Winkler, N Krüger, A Kempf, I Nehlmeier, ... Cell reports 36 (3), 2021 | 273 | 2021 |
| Omicron sublineage BQ. 1.1 resistance to monoclonal antibodies P Arora, A Kempf, I Nehlmeier, SR Schulz, HM Jäck, S Pöhlmann, ... The Lancet Infectious Diseases 23 (1), 22-23, 2023 | 140 | 2023 |
| Augmented neutralisation resistance of emerging omicron subvariants BA. 2.12. 1, BA. 4, and BA. 5 P Arora, A Kempf, I Nehlmeier, SR Schulz, A Cossmann, MV Stankov, ... The Lancet Infectious Diseases 22 (8), 1117-1118, 2022 | 102 | 2022 |
| Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA. 1, BA. 2, and BA. 3 P Arora, L Zhang, C Rocha, A Sidarovich, A Kempf, S Schulz, ... The Lancet Infectious Diseases 22 (6), 766-767, 2022 | 96 | 2022 |
| B. 1.617. 2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination P Arora, A Sidarovich, N Krüger, A Kempf, I Nehlmeier, L Graichen, ... Cell reports 37 (2), 2021 | 79 | 2021 |
| SARS-CoV-2 variants B. 1.351 and B. 1.1. 248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination M Hoffmann, P Arora, R Groß, A Seidel, B Hörnich, A Hahn, N Krüger, ... BioRxiv, 2021.02. 11.430787, 2021 | 60 | 2021 |
| Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation M Hoffmann, GMN Behrens, P Arora, A Kempf, I Nehlmeier, A Cossmann, ... The Lancet Infectious Diseases 23 (1), 25-28, 2023 | 59 | 2023 |
| Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB. 1.5 M Hoffmann, P Arora, I Nehlmeier, A Kempf, A Cossmann, SR Schulz, ... Cellular & Molecular Immunology 20 (4), 419-422, 2023 | 53 | 2023 |
| SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies P Arora, L Zhang, N Krüger, C Rocha, A Sidarovich, S Schulz, A Kempf, ... Cell host & microbe 30 (8), 1103-1111. e6, 2022 | 45 | 2022 |
| Delta variant (B. 1.617. 2) sublineages do not show increased neutralization resistance P Arora, A Kempf, I Nehlmeier, L Graichen, A Sidarovich, MS Winkler, ... Cellular & molecular immunology 18 (11), 2557-2559, 2021 | 43 | 2021 |
| Neutralisation sensitivity of the SARS-CoV-2 XBB. 1 lineage P Arora, A Cossmann, SR Schulz, GM Ramos, MV Stankov, HM Jäck, ... The Lancet Infectious Diseases 23 (2), 147-148, 2023 | 42 | 2023 |
| Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine. 2021; 65: 103255 M Hoffmann, H Hofmann-Winkler, JC Smith, N Krüger, P Arora, ... DOI 10 (2020.08), 05.237651, 2021 | 39 | 2021 |
| A system for production of defective interfering particles in the absence of infectious influenza A virus N Bdeir, P Arora, S Gärtner, M Hoffmann, U Reichl, S Pöhlmann, ... PLoS One 14 (3), e0212757, 2019 | 38 | 2019 |
| Mutation D614G increases SARS-CoV-2 transmission P Arora, S Pöhlmann, M Hoffmann Signal Transduction and Targeted Therapy 6 (1), 101, 2021 | 32 | 2021 |
| The spike protein of SARS-CoV-2 variant A. 30 is heavily mutated and evades vaccine-induced antibodies with high efficiency P Arora, C Rocha, A Kempf, I Nehlmeier, L Graichen, MS Winkler, M Lier, ... Cellular & molecular immunology 18 (12), 2673-2675, 2021 | 31 | 2021 |
| Omicron subvariant BA. 5 efficiently infects lung cells M Hoffmann, LYR Wong, P Arora, L Zhang, C Rocha, A Odle, I Nehlmeier, ... Nature communications 14 (1), 3500, 2023 | 29 | 2023 |
| Cell culture-based production and in vivo characterization of purely clonal defective interfering influenza virus particles MD Hein, P Arora, P Marichal-Gallardo, M Winkler, Y Genzel, S Pöhlmann, ... BMC biology 19 (1), 91, 2021 | 26 | 2021 |
| Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine 65: 103255 M Hoffmann, H Hofmann-Winkler, JC Smith, N Krüger, P Arora, ... J. EBIOM, 2021 | 26 | 2021 |
Stefan PöhlmannLeiter der Abteilung Infektionsbiologie, Deutsches PrimatenzentrumGeverifieerd e-mailadres voor mail.de